Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel germline JAK2 mutation in familial myeloproliferative neoplasms.
Rumi E, Harutyunyan AS, Casetti I, Pietra D, Nivarthi H, Moriggl R, Cleary C, Bagienski K, Astori C, Bellini M, Berg T, Passamonti F, Kralovics R, Cazzola M. Rumi E, et al. Among authors: bellini m. Am J Hematol. 2014 Jan;89(1):117-8. doi: 10.1002/ajh.23614. Am J Hematol. 2014. PMID: 24142793 Free article. No abstract available.
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, Them NC, Berg T, Elena C, Casetti IC, Milanesi C, Sant'antonio E, Bellini M, Fugazza E, Renna MC, Boveri E, Astori C, Pascutto C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: bellini m. Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23. Blood. 2014. PMID: 24366362 Free PMC article.
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M, Them NC, Cavalloni C, Ferretti VV, Milanesi C, Berg T, Sant'Antonio E, Boveri E, Pascutto C, Astori C, Kralovics R, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: bellini m. Blood. 2014 Apr 10;123(15):2416-9. doi: 10.1182/blood-2014-01-550434. Epub 2014 Feb 19. Blood. 2014. PMID: 24553179 Free article.
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: bellini m. Blood. 2014 Aug 14;124(7):1062-9. doi: 10.1182/blood-2014-05-578435. Epub 2014 Jul 1. Blood. 2014. PMID: 24986690 Free PMC article.
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Rumi E, Milosevic JD, Selleslag D, Casetti I, Lierman E, Pietra D, Cavalloni C, Bellini M, Milanesi C, Dambruoso I, Astori C, Kralovics R, Vandenberghe P, Cazzola M. Rumi E, et al. Among authors: bellini m. Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23. Ann Hematol. 2015. PMID: 26202607 No abstract available.
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.
Rumi E, Bertozzi I, Casetti IC, Roncoroni E, Cavalloni C, Bellini M, Sant'Antonio E, Gotti M, Ferretti VV, Milanesi C, Peroni E, Pietra D, Astori C, Randi ML, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: bellini m. Haematologica. 2015 Nov;100(11):e443-5. doi: 10.3324/haematol.2015.131458. Epub 2015 Aug 6. Haematologica. 2015. PMID: 26250575 Free PMC article. No abstract available.
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms.
Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, Sant'Antonio E, Abbonante V, Moccia F, Casetti IC, Bellini M, Renna MC, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola M. Pietra D, et al. Among authors: bellini m. Leukemia. 2016 Feb;30(2):431-8. doi: 10.1038/leu.2015.277. Epub 2015 Oct 9. Leukemia. 2016. PMID: 26449662 Free PMC article.
LNK mutations in familial myeloproliferative neoplasms.
Rumi E, Harutyunyan AS, Pietra D, Feenstra JD, Cavalloni C, Roncoroni E, Casetti I, Bellini M, Milanesi C, Renna MC, Gotti M, Astori C, Kralovics R, Cazzola M. Rumi E, et al. Among authors: bellini m. Blood. 2016 Jul 7;128(1):144-5. doi: 10.1182/blood-2016-04-711150. Epub 2016 May 23. Blood. 2016. PMID: 27216218 Free article. No abstract available.
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant'Antonio E, Cavalloni C, Casetti IC, Roncoroni E, Ciboddo M, Benvenuti P, Landini B, Fugazza E, Troletti D, Astori C, Cazzola M; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Rumi E, et al. Among authors: bellini m. Oncotarget. 2017 Oct 6;8(60):101735-101744. doi: 10.18632/oncotarget.21594. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254200 Free PMC article.
696 results